Viking Therapeutics

Company

A company that had LGD-4033 (ligandrol) in a phase two trial for hip fracture patients under the code name VK5211.

Mentioned in 1 video

Videos Mentioning Viking Therapeutics

274 - Performance-enhancing drugs and hormones—risks, rewards, & broader implications for the public

274 - Performance-enhancing drugs and hormones—risks, rewards, & broader implications for the public

Peter Attia MD

A company that had LGD-4033 (ligandrol) in a phase two trial for hip fracture patients under the code name VK5211.